Genetic suppression features ABHD18 as a Barth syndrome therapeutic target.
Masud SN, Srivastava A, Mero P, Echezarreta VS, Anderson E, van Buren L, Wei J, Taylor DT, Farias AG, Mikolajewicz N, Shaw A, Murareanu BM, Lohbihler M, Carney OS, van Heeringen S, Clijsters L, Sizova O, van Ameijde J, Nye F, Habsid A, Nedyalkova L, McDonald L, Simpson C, Wybenga-Groot L, Brown KR, Nho N, Suciu RM, Chan K, Tong AHY, Vaz FM, Evers B, Lesurf R, Papaz T, Nutter LMJ, Protze S, Billmann M, Costanzo M, Andrews BJ, Myers CL, Mital S, Vernon H, Brummelkamp TR, Boone C, Scott IC, Niphakis MJ, Strathdee D, Nijman SMB, Blomen VA, Moffat J.
Nature · journal article · DOI 10.1038/s41586-025-09373-5